HilleVax, Inc. (NASDAQ:HLVX) Short Interest Up 47.0% in August

Key Points

• HilleVax, Inc. experienced a 47.0% increase in short interest during August, rising from 241,100 to 354,500 shares.
• The stock received a "hold" rating from Zacks Research, with a consensus price target set at $2.00.
• HilleVax's institutional ownership is high, with 86.42% of its shares held by institutional investors, indicating strong confidence from major financial entities.

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 354,500 shares, an increase of 47.0% from the August 15th total of 241,100 shares. Based on an average trading volume of 624,200 shares, the short-interest ratio is presently 0.6 days. Approximately 1.6% of the shares of the company are short sold. Approximately 1.6% of the shares of the company are short sold. Based on an average trading volume of 624,200 shares, the short-interest ratio is presently 0.6 days.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded HilleVax to a "hold" rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $2.00.

Institutional Investors Weigh In On HilleVax

Hedge funds have recently made changes to their positions in the business. Millennium Management LLC raised its holdings in shares of HilleVax by 59.6% during the fourth quarter. Millennium Management LLC now owns 411,820 shares of the company's stock valued at $852,000 after buying an additional 153,815 shares during the last quarter. Two Sigma Advisers LP raised its holdings in HilleVax by 76.8% during the fourth quarter. Two Sigma Advisers LP now owns 41,200 shares of the company's stock worth $85,000 after purchasing an additional 17,900 shares in the last quarter. Federated Hermes Inc. raised its holdings in HilleVax by 128.3% during the first quarter. Federated Hermes Inc. now owns 24,429 shares of the company's stock worth $35,000 after purchasing an additional 13,728 shares in the last quarter. Northern Trust Corp raised its holdings in HilleVax by 2.8% during the fourth quarter. Northern Trust Corp now owns 249,610 shares of the company's stock worth $517,000 after purchasing an additional 6,916 shares in the last quarter. Finally, Two Sigma Investments LP raised its holdings in HilleVax by 76.3% during the fourth quarter. Two Sigma Investments LP now owns 55,535 shares of the company's stock worth $115,000 after purchasing an additional 24,039 shares in the last quarter. Institutional investors own 86.42% of the company's stock.

HilleVax Stock Performance

Shares of HLVX traded down $0.01 during mid-day trading on Tuesday, reaching $2.09. 2,800,050 shares of the company's stock traded hands, compared to its average volume of 394,760. The business's 50-day moving average price is $2.09 and its 200-day moving average price is $1.91. The stock has a market capitalization of $104.79 million, a P/E ratio of -1.46 and a beta of 0.77. HilleVax has a 12 month low of $1.34 and a 12 month high of $2.17.

HilleVax (NASDAQ:HLVX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. Equities research analysts anticipate that HilleVax will post -2.64 EPS for the current year.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.